Loyola Medicine

Patients ages 12 - 65 (inclusive) scheduled to undergo UCB transplant with HLA 4-6/6 matched umbilical cord blood graft containing >3.0 x 107 nucleated cells/kilogram (cryopreserved)) meeting one of the following disease criteria may be eligible:

Acute myeloid leukemia(AML): high-risk CR1 as evidenced by preceding myelodysplastic syndromes (MDS), high-risk cytogenetics, =two cycles to obtain CR, erythroblastic or megakaryocytic leukemia; CR2+. All patients must be in CR as defined by hematological criteria, e.g. a

Very high risk pediatric patients with AML: Patients

Acute lymphocytic leukemia: high-risk CR1 [t(9;22), t (1;19), t(4;11) or other mixed lineage leukemia rearrangements] or >one cycle to obtain CR, CR2+. All patients must be in CR as defined by hematological recovery, e.g.

Chronic myelogenous leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1), patient must have failed or be intolerant to imatinib mesylate or in accelerated phase or in second chronic phase.

MDS IPSS Int-2 or high-risk or refractory anemia with severe pancytopenia or high-risk cytogenetics: Blasts must be

Chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone B-cell lymphoma or follicular lymphoma that has progressed after at least two prior therapies: Patients with bulky disease (nodal mass >five cm) should be considered for debulking chemotherapy before transplant.

Lymphoplasmacytic lymphoma, mantle-cell lymphoma or prolymphocytic leukemia: eligible after initial therapy in CR1+ or PR1+.

Large-cell non-Hodgkin’s lymphoma (NHL) in >CR2 or >PR2: Patients in CR2 or PR2 with initial short remission (two salvage regimens) is NOT eligible.

Lymphoblastic lymphoma, Burkitt’s lymphoma and other high-grade NHL after initial therapy if stage III/IV in CR1 or PR1 or after progression if stage I/II two salvage regimens) is NOT eligible.

Multiple myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than six months, or ß-2 microglobulin >three mg/L, may be considered for this protocol after initial therapy.